Health TrialsbyHealthPanel

Biomarkers for Cognitive Decline in Intracerebral Hemorrhage

ConditionPrimary Intracerebral Hemorrhage
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorRush University Medical Center

About this trial

The goal of this clinical trial is to see if silent brain infarcts (SBIs), or stroke-like symptoms detectable during brain imaging, are a possible contributor to cognitive decline for patients diagnosed with spontaneous intracerebral hemorrhage (sICH), or blood clot in the brain. The main questions it aims to answer are

* if SBIs in sICH are associated with a lower cognitive level and more rapid cognitive decline * if SBIs in sICH are associated with certain findings on brain imaging * if SBIs in sICH are associated with higher inflammation measured by certain blood tests

Participants will undergo

* cognitive testing during hospitalization, and at 3, 6 and 12 months after the sICH * Magnetic Resonance Imaging (MRI) of the brain during hospitalization and 12 months after the sICH * blood draws during hospitalization and at 3, 6 and 12 months after the sICH

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Primary Intracerebral Hemorrhage

Age ≥ 18 and < 80 years

Disqualifiers

Pre-existing dementia

Trial population

All patients admitted to Rush University Medical Center with an intracerebral hemorrhage.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • MRI

    Diagnostic test

    MRI during hospitalization and at 12 months post sICH

  • Blood Draw

    Diagnostic test

    Will occur during hospitalization and at 3, 6 and 12 months post sICH

  • Cognitive Test

    Diagnostic test

    Cognitive testing will occur during hospitalization and at 3, 6 and 12 months post sICH

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Global Cognition

Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery

Time frame
From date of randomization and assessed throughout the during hospitalization for qualifying ICH event up to 12 months
2

Global Cognition

Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery

Time frame
3 months after hospitalization
3

Global Cognition

Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery

Time frame
6 months after hospitalization
4

Global Cognition

Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery

Time frame
12 months after hospitalization

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Rush University Medical Center

Lead sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Source ClinicalTrials.gov
Apply now